This trial will compare two effective therapies, allopurinol and febuxostat, to lower serum uric acid and therefore prevent further gout attaches. These therapies have never been compared at ...

Febuxostat 40 mg daily appears to be as efficacious as allopurinol in lowering serum uric acid levels. [38] Both febuxostat 40 and 80 mg can be given to patients with mild-to-moderate renal ...

Rheumatologists report largely adhering to American College of Rheumatology guidelines for gout management, but show notable ...

Methods: Using the Korean National Health Insurance Service (KNHIS) database, which covers the entire Korean population, we conducted a population-based cohort study among gout patients who initiated ...

Background Allopurinol is the most used urate-lowering agent for patients with gout. However, 10% of patients show intolerance to this drug, often at skin, which can be severe. Febuxostat is a novel ...

Dr. Singh says there are other medication possibilities to explore. “These patients would consider combining allopurinol plus febuxostat, pegloticase infusions, or will be left with sub-optimally ...

Among patients with gout in the US, Black individuals and those living in the South were associated with reduced adherence to allopurinol.

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some ...

and tolerability of serum uric acid lowering and maintenance with febuxostat in patients with gout. Febuxostat Open-label Clinical Trial of Urate-lowering Efficacy and Safety Adverse events were ...